Ron DePinho: CRISPR Progress in Cellular Immunotherapy
Ron DePinho, Professor and Past President of MD Anderson Cancer Center, shared a post on LinkedIn about a recent article by Heidi Ledford, adding:
”CRISPR progress in cellular immunotherapy …
Researchers used a combination of engineered viruses and virus-like particles to target T cells. The particles carried RNA and protein machinery needed for CRISPR–Cas9 gene editing, and the viruses contained the DNA encoding the CAR protein. T cells had to receive both payloads to become a CAR T cell.
In mice with leukaemia and multiple myeloma, tumors were completely wiped out in the treated mice, and more than half of the treated group with sarcomas entered full remission. A biotechnology company, Azalea Therapeutics is now testing the approach in monkeys and hopes to have clinical trials in people by the end of next year. While encouraging, it remains to be seen how long the effects of the treatment last, or whether CRISPR–Cas9 might be introducing any unwanted changes to the genome.”
Title: CRISPR makes enhanced cancer-fighting immune cells inside mice
Author: Heidi Ledford
Read the Full Article on Nature
Stay updated on all scientific advances with Hemostasis Today.
-
Jun 28, 2026, 10:34Heghine Khachatryan: Menarche as the First ‘Bleeding Challenge’
-
Jun 28, 2026, 10:13Mohammed Alharbi: Assessing Warfarin Management and Anticoagulation Quality in Older Populations
-
Jun 28, 2026, 10:03Rick Kapur: Current Understanding of FNAIT Regarding Diagnostics, Pathophysiology and Management
-
Jun 28, 2026, 09:55Utkarsh Pandey: Japan Approves Wayrilz for ITP Patients
-
Jun 28, 2026, 09:41Sung-mok Jung: How Environmental Drivers Influence SFTS Occurrence
-
Jun 28, 2026, 05:17Burcu Tunakan: Turning Collaboration into Better Outcomes for People with Hemophilia
-
Jun 28, 2026, 05:08Kathrine Kaspersen: The Power of Voluntary Plasma Donation
-
Jun 28, 2026, 04:55Sana Helani: Challenging Common Assumptions in Anemia Management
-
Jun 28, 2026, 04:55Samwel Mikaye: The Collapse of Coagulation Control in Disseminated Intravascular Coagulation